Expression of PD-L1 represents an adaptive response to proinflammatory molecules IFNγ and TNFα released from tumour-reactive effector T cells28 and represents a predictive biomarker for ICB in NSCLC; although this remains controversial.29 The gene discussed is CD274; the disease is neoplasm.